hapabapa/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) said on Thursday that India’s drug regulator has approved the launch of its Mounjaro pre-filled injector pens, expanding its options in the growing weight-loss drug market and stepping up competition with Novo Nordisk’s recently introduced Wegovy.
Lilly’s Mounjaro KwikPen, designed for once-weekly use, has been cleared by the Central Drugs Standard Control Organization for six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
The American drugmaker began selling Mounjaro in India in late March for the treatment of diabetes and obesity, initially offering only vial-based formulations in 2.5 mg and 5 mg doses.
The competition intensified earlier this week when Denmark-based Novo Nordisk (NVO) launched Wegovy in India in multiple dose strengths with a user-friendly pen injector format.